Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rani Therapeutics Holdings (RANI) Cash from Financing Activities (2020 - 2025)

Rani Therapeutics Holdings (RANI) has 6 years of Cash from Financing Activities data on record, last reported at -$1.0 million in Q3 2025.

  • For Q3 2025, Cash from Financing Activities fell 113.1% year-over-year to -$1.0 million; the TTM value through Sep 2025 reached $1.1 million, down 86.77%, while the annual FY2024 figure was $13.6 million, 5730.47% up from the prior year.
  • Cash from Financing Activities reached -$1.0 million in Q3 2025 per RANI's latest filing, down from $188000.0 in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $71.5 million in Q3 2021 and bottomed at -$3.7 million in Q1 2025.
  • Average Cash from Financing Activities over 5 years is $6.4 million, with a median of $108500.0 recorded in 2023.
  • Peak YoY movement for Cash from Financing Activities: skyrocketed 15622.45% in 2024, then tumbled 3183.47% in 2025.
  • A 5-year view of Cash from Financing Activities shows it stood at -$570000.0 in 2021, then surged by 2709.47% to $14.9 million in 2022, then tumbled by 99.35% to $96000.0 in 2023, then soared by 5753.12% to $5.6 million in 2024, then crashed by 117.96% to -$1.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Financing Activities were -$1.0 million in Q3 2025, $188000.0 in Q2 2025, and -$3.7 million in Q1 2025.